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omparison of Coronary Artery Bypass Surgery With
ercutaneous Coronary Intervention With Drug-Eluting
tents for Unprotected Left Main Coronary Artery Disease
ichael S. Lee, MD, Nikhil Kapoor, MD, Faizi Jamal, MD, Lawrence Czer, MD, Joseph Aragon, MD,
ames Forrester, MD, Saibal Kar, MD, Suhail Dohad, MD, Robert Kass, MD, Neal Eigler, MD,
lfredo Trento, MD, Prediman K. Shah, MD, Raj R. Makkar, MD
os Angeles, California
OBJECTIVES This study evaluated the clinical outcomes of consecutive, selected patients treated with
coronary artery bypass graft (CABG) surgery or percutaneous coronary intervention (PCI)
with drug-eluting stents (DES) for unprotected left main coronary artery (ULMCA) disease.
BACKGROUND Although recent data suggest that PCI with DES provides better clinical outcomes compared
to bare-metal stenting for ULMCA disease, there is a paucity of data comparing PCI with
DES to CABG.
METHODS Since April 2003, when DES first became available at our institution, 123 patients underwent
CABG, and 50 patients underwent PCI with DES for ULMCA disease.
RESULTS High-risk patients (Parsonnet score 15) comprised 46% of the CABG group and 64% of
the PCI group (p  0.04). The 30-day major adverse cardiac and cerebrovascular event
(MACCE) rate for CABG and PCI was 17% and 2% (p  0.01), respectively. The mean
follow-up was 6.7 6.2 months in the CABG group and 5.6 3.9 months in the PCI group
(p  0.26). The estimated MACCE-free survival at six months and one year was 83% and
75% in the CABG group versus 89% and 83% in the PCI group (p  0.20). By multivariable
Cox regression, Parsonnet score, diabetes, and CABG were independent predictors of
MACCE.
CONCLUSIONS Despite a higher percentage of high-risk patients, PCI with DES for ULMCA disease was
not associated with an increase in immediate or medium-term complications compared with
CABG. Our data suggest that a randomized comparison between the two revascularization
strategies for ULMCA may be warranted. (J Am Coll Cardiol 2006;47:864–70) © 2006 by
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.09.072the American College of Cardiology Foundation
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T
aignificant left main coronary artery disease occurs in 5%
o 7% of patients undergoing coronary angiography (1,2).
atients with unprotected left main coronary artery
ULMCA) disease treated medically have a three-year
ortality rate of approximately 50% (3,4). Based on the
esults of several trials that consistently demonstrated a
urvival benefit in patients treated with coronary artery
ypass graft (CABG) surgery over medical therapy (5–7),
he current standard of care for treatment of ULMCA
tenosis is CABG.
See page 878
On the other hand, the high rate of early restenosis, acute
hrombotic occlusion, and mortality associated with percu-
aneous coronary intervention (PCI) in earlier clinical stud-
es has led the American College of Cardiology and Amer-
can Heart Association to discourage PCI for ULMCA (8).
ince these guidelines were established, newer technology
From Cedars-Sinai Medical Center, University of California, Los Angeles School
f Medicine, Los Angeles, California.i
Manuscript received June 16, 2005; revised manuscript received August 10, 2005,
ccepted September 8, 2005.nd percutaneous techniques for revascularization have been
eveloped.
Re-evaluation of the optimal treatment for ULMCAmay
e important, especially in light of recent observational data
uggesting that ULMCA PCI with sirolimus-eluting stents
Cypher, Cordis, Johnson & Johnson Corp., Miami, Flor-
da) and paclitaxel-eluting stents (Taxus, Boston Scientific
orp., Natick, Massachusetts) may be safe and effective in
ecreasing in-stent restenosis when compared to bare-metal
tents (9–11). However, the efficacy of PCI with drug-
luting stents (DES) on short- and intermediate-term
linical outcomes on ULMCA disease compared to CABG
s unknown. We report on the short- and intermediate-term
afety and efficacy of 173 consecutive patients with
LMCA disease who underwent either PCI with DES or
ABG in a single institution.
ETHODS
tudy population. Since April 2003, when DES first
ecame available at our institution, 195 consecutive patients
ith ULMCA disease underwent revascularization.
wenty-two patients underwent concomitant valve surgery
nd were excluded from comparative analysis. The remain-
ng 173 patients constitute our study population of 50
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February 21, 2006:864–70 CABG Versus DES for Left Main Artery Stenosisatients who underwent PCI with DES and 123 patients
ho underwent CABG for ULMCA disease.
The primary clinical end points were freedom from major
dverse cardiac and cerebrovascular events (MACCE) at 30-
ay and intermediate-term follow-up. We included patients
ith ULMCA stenoses or documented myocardial ischemia
nd50% diameter stenosis of the ULMCA on angiography.
he left main coronary artery was defined as unprotected if
here were no CABGs to the left anterior descending artery
nd left circumflex artery. Patients were jointly evaluated by
ardiac surgery and interventional cardiology consultants. The
nal decision of the method of revascularization was made
fter comprehensive review of all relevant factors. To be
elected for PCI, a patient had to have one of the following
haracteristics: very high risk for CABG, limited life expect-
ncy, patient refusal to undergo CABG with a preference for
CI, or patient deemed unsuitable for CABG by the cardiac
urgeon. This study was approved by the Cedars-SinaiMedical
enter Institutional Review Board.
CI. Percutaneous coronary intervention was performed us-
ng the standard percutaneous transfemoral approach, except
or two patients who underwent PCI via the transradial
pproach due to extensive peripheral vascular disease. Lesions
n the ostium or body of the ULMCA without distal bifurca-
ion involvement were usually treated with a single stent.
everal techniques were used for the treatment of distal
ifurcation disease. Stenting across the left circumflex artery,
imultaneous kissing stenting, T stenting, and the crush
echnique have been previously described (12,13). The choice
f a sirolimus-eluting stent or paclitaxel-eluting stent and
ntithrombotic agent was made by the operator. High-
ressure stent deployment was performed using an initial
nflation of 16 atm. Intravascular ultrasound was used to
onfirm optimal stent deployment. Post-dilation with addi-
ional balloons was performed for optimal stent apposition.
lycoprotein IIb/IIIa antagonists and intra-aortic balloon
ump were used if clinically indicated. All patients received
spirin (325 mg/day) indefinitely and a loading dose of 300
g of clopidogrel. Clopidogrel was continued for at least six
onths. Cardiac enzymes were not measured routinely
nless there was a clinical suspicion of ischemia, and
herefore was not a designated outcome of the study.
ypass surgery. Standard bypass techniques included a left
nternal mammary artery for revascularization of the left
nterior descending coronary artery whenever possible and
Abbreviations and Acronyms
ARTS  Arterial Revascularization Therapies Study
CABG  coronary artery bypass graft
DES  drug-eluting stent
MACCE  major adverse cardiac and cerebrovascular
event
PCI  percutaneous coronary intervention
ULMCA  unprotected left main coronary arteryold potassium cardioplegia. Cardiac enzymes were not geasured routinely unless there was a clinical suspicion of
schemia.
efinitions. Percutaneous coronary intervention proce-
ural success was defined as Thrombosis In Myocardial
nfarction (TIMI) flow grade 3 with a final residual stenosis
f 30% without death, myocardial infarction, or emer-
ency CABG before hospital discharge. Death was defined
s any post-procedure death. A myocardial infarction was
efined as ischemic symptoms associated with cardiac en-
yme elevation 3 times the upper limit of the normal
alue. Target vessel revascularization was defined as a repeat
evascularization to treat a luminal stenosis within the stent
r within 5-mm distal and proximal segments adjacent to
he stent, including the ostium of the left anterior descend-
ng artery and/or left circumflex artery. A cerebrovascular
vent was defined as stroke, transient ischemic attack,
eversible ischemic neurologic deficit, or coma.
The Parsonnet score was used to stratify the risk of death
t 30 days in patients undergoing cardiac surgery (14,15). A
arsonnet score 15 identified patients at high risk for
urgical mortality.
tatistics. Continuous variables are presented as mean 
D and were compared by Student t test (when the group
istributions were symmetrical and mounded) or Mann-
hitney U test (when the group distributions were
kewed). The Satterthwaite adjustment was applied to the t
est when there was evidence against equality of variance.
he chi-square test (when all expected cell counts were 5)
r Fisher exact test (when any expected cell count was 5)
as used to determine the significance of differences in
ategorical variables. Survival curves were generated by the
aplan-Meier method, and the differences were assessed by
he log-rank test. Survival analyses were performed for the
rst 423 days of follow-up so that the comparison of CABG
nd PCI would be over the same time period. A multi-
ariable Cox proportional hazard model was created with
he use of baseline clinical and angiographic characteristics
nd procedure-related variables in order to identify inde-
endent predictors of MACCE. All statistical tests were
wo-tailed, and a significance level of 0.05 was used
hroughout. Statistical analyses were performed using SPSS
ersion 10.0 (SPSS Inc., Chicago, Illinois).
ESULTS
aseline characteristics. Baseline clinical and demo-
raphic characteristics are listed in Table 1. Compared to
he CABG group, the PCI group had less men (50% vs.
6%, p  0.01), more patients with chronic renal insuffi-
iency (16% vs. 5%, p  0.02), and more patients with
nstable angina as the presenting symptom (46% vs. 25%,
 0.01). The average Parsonnet score was 13.7  9.7 in
he CABG group and 18.3  10.9 in the PCI group (p 
.01). High-risk patients (Parsonnet score 15) were
resent in 46% of the CABG group and 64% of the PCI
roup (p  0.04).
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CABG Versus DES for Left Main Artery Stenosis February 21, 2006:864–70Nine patients (18%) who underwent PCI were turned
own for CABG after surgical consultation. All patients
ith isolated ostial or mid-body disease received one stent.
total of 60% in the PCI group had distal bifurcation
isease.
rocedural outcomes. Procedural characteristics are pre-
ented in Table 2. The procedural success rate was 98% in
able 1. Baseline Clinical Characteristics
CABG
n  123
PCI
n  50
p
Value
ge (yrs  SD) 70  10 72  15 0.33
en (%) 76 50 0.01
ypertension (%) 81 88 0.37
iabetes mellitus (%) 31 36 0.48
ypercholesterolemia (%) 72 74 0.85
urrent smoker (%) 19 12 0.29
hronic renal insufficiency
(Cr 1.5 mg/dl)
5 16 0.02
revious stroke 10 8 0.72
linical presentation 0.02
Stable angina (%) 55 34
Unstable angina (%) 25 46
Myocardial infarction (%) 20 20
jection fraction (%  SD) 52  10 51  15 0.64
arsonnet score (mean  SD) 13.7  9.7 18.3  10.9 0.01
ercent of patients with
Parsonnet score 15
46 64 0.04
ABG  coronary artery bypass graft surgery; Cr  creatinine; PCI  percutaneous
oronary intervention; SD  standard deviation.
able 2. Procedural Characteristics for CABG and PCI
ABG
Grafts per patient 3.0  0.8
IMA-to-LAD graft (%) 96
CI
Disease location
Ostial (%) 42
Mid (%) 20
Distal bifurcation (%) 60
Stent deployment technique for distal
bifurcation disease
Single stent crossing over LCX (%) 33
Crush technique (%) 40
T stenting (%) 10
Simultaneous kissing stenting (%) 17
PCI technique for distal bifurcation disease
Single stent (%) 33
Bifurcation stenting (%) 67
PCI of other coronary lesions (%) 66
Cypher stent (%) 84
Taxus stent (%) 16
Stents per patient 2.5  1.4
Final diameter of stent (mm) 3.7  0.47
Total stent length (mm) 43.2  28.4
Guidance with IVUS (%) 74
Hemodynamic support with IABP (%) 64
TandemHeart percutaneous left ventricular
assist device (%)
6
Concomitant valvuloplasty (%) 2
Glycoprotein IIb/IIIa antagonists (%) 14
ABP  intra-aortic balloon pump; IMA  internal mammary artery; IVUS b
ntravascular ultrasound; LAD  left anterior descending artery; LCX  left
ircumflex artery; other abbreviations as in Table 1.he PCI group. Intra-aortic balloon pump was used in 32
atients (64%), and the TandemHeart percutaneous left
entricular assist device (CardiacAssist Inc., Pittsburgh,
ennsylvania) was used in 3 patients (6%). Forty-two
atients (84%) underwent PCI with sirolimus-eluting stents
nd eight patients (16%) with paclitaxel-eluting stents. On
verage, 2.5  1.4 stents were implanted with a total stent
ength of 43.2  28.4.
In the CABG group, 3.0  0.8 grafts per patient were
sed, with 96% of patients receiving an internal mammary
rtery conduit to the left anterior descending artery.
0-day outcomes. The 30-day clinical outcomes are sum-
arized in Table 3. The cerebrovascular event rate was
igher in the CABG group (8% vs. 0%, p 0.03), but there
as no statistically significant difference in mortality (5% vs.
%, p  0.34). In the CABG group, there were six
n-hospital deaths (four from cardiac reasons, one from a
troke, and one from a pneumothorax). The one death in
he PCI group occurred in a patient with a Parsonnet score
f 41 who was turned down by cardiac surgery because the
atient was considered a high-risk candidate for CABG.
his patient underwent peripheral vascular surgery two days
fter her PCI and died suddenly eight days after surgery.
ne CABG patient underwent emergent PCI on the
econd post-operative day for an ST-segment elevation
yocardial infarction secondary to the occlusion of a saphe-
ous vein graft that was anastomosed to the posterior
escending artery. No patient required urgent target vessel
evascularization in the PCI group. No statistically signifi-
ant differences in myocardial infarction were observed
able 3. Procedural and 30-Day Outcomes
CABG PCI
p
Value
ACCE (%) 17 2 0.01
eath (%) 5 2* 0.34
yocardial infarction† (%) 2 0 0.9
rgent target vessel
revascularization (%)
1 0 0.9
erebrovascular events (%) 8 0 0.03
T/VF (%) 9 0 0.03
equirement for permanent
pacemaker (%)
4 0 0.15
enal failure requiring dialysis (%) 2 0 0.9
essel perforation (%) NA 2
ardiac tamponade (%) 1 2 0.9
ascular hematoma requiring
vascular repair (%)
0 0 0.9
epeat surgery for bleeding (%) 7 NA
n-hospital length of stay
(days  SD)
7.6  4.9 3.9  4.5 0.01
One patient with a Parsonnet score of 41 had severe peripheral vascular disease and
eft ventricular dysfunction and was turned down by the surgeon for CABG. The
atient underwent PCI with a percutaneous left ventricular assist device for hemo-
ynamic support. The patient underwent peripheral vascular surgery 2 days after PCI
nd died suddenly 10 days after PCI. †Only post-hospitalization and/or clinical
yocardial infarction as cardiac enzymes were not drawn serially after revascularization.
MACCE  major adverse cardiac and cerebrovascular event; VF  ventricular
brillation; VT  ventricular tachycardia; other abbreviations as in Table 1.etween the two groups (2% vs. 0%, p  0.9). The overall
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February 21, 2006:864–70 CABG Versus DES for Left Main Artery StenosisACCE rate was higher in the CABG group (17% vs. 2%,
 0.01).
There were also other significant post-operative compli-
ations in the CABG group. Eight patients (7%) required
epeat operation for bleeding (1 for cardiac tamponade), 6
atients (5%) developed pneumonia, 5 patients (4%) re-
uired permanent pacemaker implantation, 8 patients (7%)
eveloped pleural effusions requiring thoracocentesis, 2
atients (2%) developed renal failure requiring hemodialysis,
nd 11 patients (9%) developed ventricular tachycardia/
entricular fibrillation.
One patient in the PCI group developed a cardiac tam-
onade requiring emergent pericardiocentesis secondary to a
ire perforation. No patient required permanent pacemaker
mplantation, developed acute renal failure requiring hemodi-
lysis, or had vascular complications like major hematoma,
seudoaneurysm, or need for vascular repair at the access
ite.
Patients treated with CABG had significantly longer
ospitalization compared with patients treated with PCI
igure 1. Major adverse cardiac and cerebrovascular events (including de
zation) (MACCE)-free survival (A). Freedom from death (the second dea
Parsonnet score of 23 who was a “do not resuscitate/do not intubate” pati
ransfusion) (B). Freedom from target vessel revascularization (all three pati
ad focal in-stent restenosis at the ostium of the left circumflex artery, a
escending artery) (C). Freedom from death, myocardial infarction, and c7.6  4.9 days vs. 3.9  4.5 days, p  0.01). vntermediate follow-up. The mean follow-up was 6.7 
.2 months in the CABG group and 5.6  3.9 months in
he PCI group (p  0.26). The estimated MACCE-free
urvival at six months and one year was 83% and 75% in the
ABG group versus 89% and 83% in the PCI group
p  0.20) (Fig. 1A). The estimated freedom from death at
ix months and one year was 87% and 85% in the CABG
roup versus 96% and 96% in the PCI groups (p 0.18). In
he CABG group, there were seven deaths at intermediate
ollow-up (two from cardiac reasons, one from a stroke, one
rom an abdominal aortic aneurysm rupture, one from
espiratory failure secondary to pneumonia, one from renal
ailure, and one from suicide). The second death in the PCI
roup was in a patient with a Parsonnet score of 23 who was
“do not resuscitate/do not intubate” patient who died after
eveloping acute pulmonary edema following an outpatient
lood transfusion (Fig. 1B). Angiographic follow-up in the
CI group was available in 21 patients (42%). The esti-
ated freedom from target vessel revascularization at six
onths and one year was 99% and 95% in the CABG group
yocardial infarction, cerebrovascular events, and target vessel revascular-
the percutaneous coronary intervention [PCI] group was in a patient with
ho died after developing acute pulmonary edema after an outpatient blood
ho underwent repeat PCI had distal bifurcation involvement; two patients
e patient had focal in-stent restenosis at the ostium of the left anterior
vascular events (D). CABG  coronary artery bypass graft.ath, m
th in
ent w
ents wersus 93% and 87% in the PCI group (p 0.22) (Fig. 1C).
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CABG Versus DES for Left Main Artery Stenosis February 21, 2006:864–70ll three patients who underwent repeat PCI (two patients
nderwent balloon angioplasty and one patient underwent
epeat PCI with DES) had distal bifurcation involvement.
wo of these three patients returned with re-restenosis and
nderwent CABG. Two additional patients in the PCI
roup underwent repeat PCI for de novo lesions in the distal
eft anterior descending artery. The estimated freedom from
eath, myocardial infarction, and cerebrovascular events at
ix months and one year was 83% and 79% in the CABG
roup versus 96% and 96% in the PCI group (hazard ratio,
.4 [95% confidence interval, 1.0 to 18.6]; p  0.03) (Fig.
D).
redictors of intermediate MACCE. The following vari-
bles were entered into a stepwise multivariable Cox
roportional hazard model for MACCE-free survival:
ge, gender, diabetes mellitus, Parsonnet score, ejection
raction, chronic renal insufficiency, myocardial infarc-
ion, and CABG. The significant univariate predictors
ere Parsonnet score, diabetes mellitus, and myocardial
nfarction (Table 4). In the final Cox model, the significant
redictors of the hazard of MACCE were Parsonnet score,
iabetes mellitus, and CABG.
ISCUSSION
he most important finding of our study is that in a pilot
xperience with ULMCA, treatment with PCI with DES
esulted in outcomes equivalent to CABG. Patients in the
CI group were of comparable pre-operative risk using
raditional cardiac surgery criteria.
Our study adds to the existing database comparing PCI
o CABG in angiographic subsets of coronary artery disease.
n several studies comparing PCI with bare-metal stents to
ABG in multivessel coronary artery disease, no mortality
enefit was demonstrable, although there was a lower
equirement for target vessel revascularization with CABG
16–18). On the other hand, the Arterial Revascularization
herapies Study II (ARTS II) (19), a nonrandomized
omparison of CABG and PCI with DES in patients with
ultivessel coronary artery disease, did not demonstrate an
ncreased need for repeat revascularization in the PCI arm.
t present, therefore, it is not known whether the improved
utcomes in PCI with DES will be extended to patients
ith ULMCA disease. Our observational study suggests
able 4. Cox Proportional Hazard Model Results
Variables p Value Hazard Ratio (95% CI)
nivariate analysis
Myocardial infarction 0.01
Parsonnet score 0.01
Diabetes mellitus 0.01
ultivariable analysis
Parsonnet score 0.01 1.1 (1.0–1.1)
Diabetes mellitus 0.03 2.2 (1.1–4.6)
CABG (vs. PCI) 0.04 2.8 (1.0–7.4)
I  confidence interval; other abbreviations as in Table 1.hat, in the ULMCA subset, PCI may provide a comparable (r lower rate of death, myocardial infarction, and cerebro-
ascular events compared to CABG, when patients are
ssigned to treatment by consensus of interventionalist and
ardiac surgeon. On the other hand, we do not have
ong-term follow-up data, although long-term data (up to
our years) in other angiographic subsets suggest that
irolimus-eluting stents have a low rate of in-stent restenosis
20). The ongoing prospective Synergy Between PCI and
axus and Cardiac Surgery (SYNTAX) and Revasculariza-
ion Comparing Surgery Versus Percutaneous Coronary
ntervention for Unprotected Left Main Artery Stenosis
andomized Evaluation (REVASCULARIZE) trials will
dd more data for analysis of this issue, especially in
ifurcation disease.
Our CABG 30-day (4.9%) and 6-month (11.4%) mor-
ality rates are consistent with the published data for CABG
or ULMCA disease. The Society of Thoracic Surgery
eported an in-hospital mortality of 3.9% in patients with
eft main disease (21). The Cleveland Clinic Foundation
eported 2.3% in-hospital mortality and 11.3% one-year
ortality (22). In patients who were considered to be low
urgical risk, with age 65 years and New York Heart
ssociation heart failure class 2, the one-year mortality
as 5.7%. d’Allonnes et al. (23) reported an early post-
perative mortality of 4.7% in 106 patients with ULMCA
tenosis who underwent CABG.
Although our patients were selected for either PCI or
ABG based on consensus of clinical judgment of the
ardiologist and surgeon, the surgical risk of the patient
roups was comparable. Overall, patients with high Parson-
et scores constituted 51% of the patient population (64% in
he PCI group and 46% in the CABG group). Included in
he 50 PCI patients were patients with multivessel coronary
rtery disease, cardiogenic shock, orthotopic heart trans-
lant, orthotopic lung transplant, and three patients on
ercutaneous left ventricular assistance. There was a rela-
ively low 30-day mortality rate (2%) in the PCI group
espite the majority of patients being at high surgical risk
or mortality and no deaths in the PCI group with low-risk
arsonnet scores.
Intra-aortic balloon pumps were used in 64% of our
atients who underwent PCI of ULMCA with DES
ompared to 4.9% in Park et al. (9), 21.2% in Chieffo et al.
10), and 15% in Valgimigli et al. (11). Three other patients
nderwent ULMCA PCI with the TandemHeart percuta-
eous left ventricular device. Hemodynamic support with
he intra-aortic balloon pump and the percutaneous left
entricular assist device was frequently used because we
hose to be very cautious in this early experience with PCI
f ULMCA.With more experience, we currently do not use
ntra-aortic balloon pumps in low-risk patients with normal
eft ventricular function.
A total of 14% of patients received glycoprotein IIb/IIIa
ntagonists in our study compared to 7.8% in Park et al. (9),
8% in Valgimigli et al. (11), and 28.5% in Chieffo et al.
10). The impact of glycoprotein IIb/IIIa antagonists on
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February 21, 2006:864–70 CABG Versus DES for Left Main Artery Stenosisatients undergoing ULMCA PCI has not been studied in
randomized clinical trial and is thus unknown.
One previously reported limitation of PCI in ULMCA
hat involves the distal bifurcation is the high incidence of
estenosis at the ostium of the left circumflex artery (9–11).
atients in our study with distal bifurcation disease also had
greater need for target vessel revascularization. All three of
he cases of target vessel revascularization were in patients
ith distal bifurcation disease involving the ULMCA com-
ared to no patients with ostial and mid-body lesions.
athology studies of bifurcation lesions suggest that arterial
ranch points are predisposed to the development of ath-
rosclerotic plaque, thrombus, and inflammation due to low
hear and low flow velocities (24–26). Although the ideal
CI strategy for dealing with distal bifurcation lesions is still
ndefined, our preliminary experience suggests that in this
ondition, it may be difficult to match the clinical outcomes
f a left internal mammary to the left anterior descending
rtery graft, which has a patency rate of more than 90% at
0 years and improves survival and freedom from further
ardiovascular events (27,28).
The optimal treatment of restenosis after PCI of ULMCA
ith DES is unknown. The percentage of patients who
nderwent CABG as their mode of revascularization ranged
rom 0% to 50% (9–11). In our study, two of three patients
ho underwent repeat PCI (one patient underwent balloon
ngioplasty and the other patient underwent repeat PCI
ith DES) returned with re-restenosis and subsequently
nderwent CABG. Because the outcomes of repeat PCI for
estenosis of ULMCA are not well defined, it is reasonable
o recommend CABG as the primary treatment modality
or patients with restenosis after PCI with DES.
otential clinical implications of data. Our data suggest
hat PCI in ULMCA disease is safe when patients are
llocated by clinical judgment. Because PCI showed trends
oward benefit in a number of outcome variables, it is
ossible that a large sample size might have revealed other
tatistically significant outcome variables. On the other
and, there may be an incidence of very late complications
ssociated with DES that will be defined with longer-term
ollow-up. A randomized trial certainly seems indicated. It
s important to recognize, however, that randomization, as
ith all trials comparing CABG to PCI, eliminates clinical
udgment in patient selection and carries a potential for
eing misleading as a predictor of outcomes in actual clinical
ractice.
tudy limitations. The nonrandomized nature of the study
imits any direct comparisons of the two methods of
evascularization. We included all patients with ULMCA
isease, resulting in a heterogeneous population of patients.
lthough trial strategies often seek to determine if one
ption is superior to another, our trial cannot be interpreted
n this manner. Rather, it demonstrates that comparable
esults can be obtained in clinical practice when consensus
udgment is utilized. Another potential limitation is that
lmost all of the PCI of the ULMCA was performed by onerimary operator. Thus, the results obtained in this study
ay not be applicable to the broad population of interven-
ional cardiologists. The majority of the patients received
ypher stents (Cordis, Johnson & Johnson Corp.) (42 out
f 50 patients). Therefore, the limited experience with
axus stents may preclude extrapolating these data to all
ES. Periprocedural cardiac enzyme levels were not serially
rawn after PCI or CABG. The reported myocardial
nfarction rate in both revascularization strategies is only the
ost-hospitalization and/or clinical myocardial infarction
ate and not the usually reported myocardial infarction rate
n clinical trials. Absence of these data could be important,
ecause creatine kinase-MB was considered to be a major
redictor of clinical outcome in the CABG arm of the
RTS I trial, which compared PCI with bare metal stents
o CABG in multivessel coronary artery disease (19). Our
rial did not include any asymptomatic patients, so potential
utcomes in this subset remain undefined. Our follow-up
as somewhat less rigorous in the CABG group, because
symptomatic patients in this group were not subjected to
outine follow-up angiography, and the length of follow-up
s currently not quite equal in the two groups. Although we
ncourage follow-up angiography at three to six months,
here was a low incidence of angiographic follow-up (42%)
ue to patients refusing repeat angiography. Currently, it is
ur policy not to offer ULMCA PCI to patients unless they
gree to follow-up angiography. Finally, we did not conduct
uantitative analysis of symptom or functional improvement
n both groups.
onclusions. In this observational study, PCI with DES
as found to be a viable alternative to CABG, with no
ncrease in short- and intermediate-term MACCE in pa-
ients with ULMCA disease compared with CABG, when
linical judgment was used for patient allocation. These
esults suggest a potential need for a large, multicenter,
andomized study with long-term follow-up to provide a
asis for re-evaluation of treatment guidelines for ULMCA
isease.
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